Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

President Obama's Declaration Of National Emergency Triggers H1N1 Jitters Halfway Around The World In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - As government leaders mull whether to temporarily close down all schools across South Korea, and amid jitters caused by the declaration of a national emergency in the U.S. by President Barack Obama, the Korea Food & Drug Administration has given the green light to Korean biotech outfit Green Cross to use its new vaccine in the country's inoculation drive against A/H1N1

You may also be interested in...



Korean Government Raises H1N1 Alert Level to Highest Yet; Forms Anti-disaster Team

SEOUL - In a move to counter the fast-paced spread of the A/H1N1 virus, which is taking on epidemic proportions now in South Korea, the government on Tuesday raised its national health alert to the highest "Red" level

Korean Government Raises H1N1 Alert Level to Highest Yet; Forms Anti-disaster Team

SEOUL - In a move to counter the fast-paced spread of the A/H1N1 virus, which is taking on epidemic proportions now in South Korea, the government on Tuesday raised its national health alert to the highest "Red" level

As Pandemic Spreads, South Korea Could Order Country-wide Closure Of Schools, Increase Antiviral Stockpiles

SEOUL - Amid growing pressure from doctors for the compulsory closure of all schools across the nation to slow the spread of H1N1, South Korea's health minister Jeon Jae-Hee, has publicly vowed that the government will speedily secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir), the leading antiviral drugs

Related Content

UsernamePublicRestriction

Register

SC070167

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel